Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Silence Therapeutics ( (SLN) ) just unveiled an announcement.
On May 18, 2026, Silence Therapeutics entered a new Open Market Sale Agreement with Jefferies LLC, allowing the biotech group to sell American Depositary Shares from time to time in at-the-market offerings, replacing a prior 2021 agreement that was terminated the same day. The company is not obligated to issue any ADSs, will pay Jefferies up to a 3% commission on sales, and plans to use a newly filed shelf registration statement once it is declared effective by the U.S. Securities and Exchange Commission.
Silence also updated investors that, following further analysis, it now believes it should not have been classified as a passive foreign investment company for the tax year ended December 31, 2025, although it warned its PFIC status could vary in future years. The company highlighted that any PFIC classification could carry adverse U.S. tax consequences for American holders of its shares or ADSs and said it does not currently expect to provide the tax information required for certain PFIC-related elections for that year.
The most recent analyst rating on (SLN) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Silence Therapeutics stock, see the SLN Stock Forecast page.
Spark’s Take on SLN Stock
According to Spark, TipRanks’ AI Analyst, SLN is a Neutral.
The score is held down primarily by weak financial performance (large losses and ongoing cash burn), with only partial offsets from low balance-sheet leverage and a mixed-to-improving medium-term technical backdrop. Valuation is constrained by negative earnings, while recent corporate updates are mixed (pipeline progress but a partner stepping away and a widening net loss).
To see Spark’s full report on SLN stock, click here.
More about Silence Therapeutics
Silence Therapeutics plc is a biotechnology company that develops RNA-based therapeutics, with its American Depositary Shares (ADSs) listed on The Nasdaq Global Market. The company targets global investors through its ADS structure, with each ADS representing three ordinary shares, and operates within a regulatory framework that includes U.S. securities and tax considerations for its shareholders.
Average Trading Volume: 326,849
Technical Sentiment Signal: Sell
Current Market Cap: $288.1M
For a thorough assessment of SLN stock, go to TipRanks’ Stock Analysis page.